Hemostasis Today

February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
Wolfgang Miesbach: How ‘Benign’ PDE Inhibitors Shape Platelet Function
Feb 10, 2026, 16:16

Wolfgang Miesbach: How ‘Benign’ PDE Inhibitors Shape Platelet Function

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn about a recent article by Meinrad Paul Gawaz et al, published in  ScienceDirect:

”Do ‘benign’ PDE inhibitors quietly shape platelet function?

A recent study by Meinrad Paul Gawaz and co-authors from the University of Tübingen investigates how different phosphodiesterase (PDE) inhibitors modulate platelet signalling and thrombus formation via cAMP/cGMP pathways.

What the authors explored

They compared:

  •  A broad PDE blocker
  •  A PDE‑3–preferring inhibito
  •  A PDE‑5 inhibitor

across platelet activation, aggregation assays and a collagen flow‑chamber models:

  •  ADP/P2Y12‑ and TRAP/PAR1‑driven platelet responses are more sensitive to PDE inhibition than collagen/GPVI signalling.
  •  Robust inhibition of activation and aggregation requires broad or combined PDE targeting, rather than blocking a single isoform.
  • Under arterial shear, all tested inhibitors – including a PDE‑5 blocker – reduce thrombus formation, revealing effects not seen in routine PRP assays.

Why this matters

For patients on chronic PDE‑3/5 therapy (e.g. for vascular disease, pulmonary hypertension, erectile dysfunction), there may be a ‘hidden’ antithrombotic modulation that becomes clinically relevant when combined with aspirin, P2Y12 inhibitors or DOACs.”

Title: Effect of phosphodiesterase inhibitors on platelet function

Authors: Ravi Hochuli, Valerie Dicenta, Zoi Laspa, Manuel Sigle, Tobias Harm, Tatsiana Castor, Anne-Katrin Rohlfing, Meinrad Paul Gawaz

Read the Full Article on  ScienceDirect.

Wolfgang Miesbach: How ‘Benign’ PDE Inhibitors Shape Platelet Function

Find more posts  featuring Wolfgang Miesbach on Hemostasis Today.